Introduction
C h ro n ic obstructive pulm onary disease (COPD) is characterised by progressive loss of lung function and oxygen uptake capacity. As a consequence, extensive morbidity and mortality do occur in these patients due to complications of hypoxaemia such as polycythaemia, pulmonary hypertension, cor pulmonale and cardiac arrhyth mias. In the course of the disease, periods with arterial oxygen desaturations may first occur dur ing R EM sleep [1] , due to hypoventilation [2] . Prospective studies estimate that this occurs in 25-100% of the patients with COPD who are normoxaemic during the day, depending on the definition of desaturation and the severity of the disease [1, 3, 4] .
T reatm ent modalities to improve nocturnal saturation in these patients include supplemental oxygen, respiration-stimulating agents, assisted ventilation and training of the respiratory mus cles. In this article we will discuss some aspects of * Tel.: (31-8895) 59911; fax: ( + 31-8895) 59290. the breathing disorders during sleep that may occur in patients with COPD and the different treatment modalities.
Diagnosis

Polysomnography
Nocturnal breathing disorders and their under lying mechanisms can be assessed by polysomnog raphy. During the night arterial oxygen satura tion, carbon dioxide tension measured in respira tory air, arterially or transcutaneously, thoraco abdominal movements, oscillation in oesophageal pressure and sleep stages are recorded. Sleep stages are recorded to define the adequancy of sleep, i.e. is there enough sleep to be representa tive, and conformation of REM sleep to catch the presence of REM sleep-related phenomena [5] . When analysing polysomnography records, sev eral irregular breathing patterns can be distin guished. Central apnoea is defined as the absence of P C 0 2 oscillations or oro-nasal airflow for at least 10 s, in combination with absent chest wall 0300-2977/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved SSD I 0300-2977(95)00080-1 Y.F. Heijdra et a l /Netherlands Journal o f Medicine 47 (1995) 296-301 297 movements or oesophageal pressure swings. Ob structive apnoea is defined as the absence of P C 0 2 oscillations or oro-nasal airflow for at least 10 s, in combination with a normal or decreased chest wall movement. Hypopnoea is defined as an episode of alveolar hypoventilation of at least 10 s detected by an increase in P C 0 2. Central hypop noea is caused by a decrease in central ventilatory drive, and ideally it should be deduced from a parameter that measures ventilatory drive more or less directly. Integrated respiratory muscle EM G or oesophageal pressure oscillations are such parameters. Indirect parameters of a de crease in ventilatory drive, such as movements of the thoracic wall, should be interpreted with ex treme caution. The term central hypoventilation is often used to indicate hypoventilation of a non obstructive origin, such as respiratory muscle fail ure, although the latter is no central problem in the strict sense. Obstructive hypopnoea is associ ated with a normal or even increased central ventilatory drive and decreased ventilation. A combination of central and obstructive breathing disorders may also be present. These irregular breathing patterns occur most frequently during REM sleep.
Several studies have tried to find daytime pa rameters to predict nocturnal saturation in pa tients with COPD, because nocturnal hypoxaemia caused by central hypopnoea is often symptomless. Although, polycythaemia, pulmonary hyper tension, cor pulmonale, morning headache or generalised fatigue indicate the presence of se vere disturbances. Daytime S a 0 2 (r = 0.87), P a C 0 2 ( r = -0.73), F E^ (r = 0.61), the hyper capnie ventilatory response (HCVR) (r = 0.41) and maximal inspiratory mouth and transdiaphragmatic pressures (r = 0.65 and 0.53, respec tively) are related to nocturnal saturation in groups of patients [4, 6, 7] . However, none of these variables is able to predict nocturnal saturation in the individual patient, precisely enough to re place polysomnography. Therefore, polysomnog raphy or a screening oximetry is advised in pa tients with a daytime P a 0 2 between 7.3-11.0 kPa combined with one of the following disorders: polycythaemia, pulmonary hypertension, cor pul monale, PaCOa > 45 mmHg, morning headache or generalised fatigue [8] , an H CV R below 3.5 1 • m in" 1 • kPa~* [4] or low maximal inspiratory pressures (females < 5.0 kPa, males < 7.5 kPa) [9] .
M echanism s involved in the occurrence o f noc turnal desaturations
In many patients with COPD, transient de creases in nocturnal arterial oxygen saturation occur. This may be caused by a variety of factors. The importance of these factors will be outlined below.
Hypoventilation ("central hypopnoea"); During sleep, ventilation is reduced in normal subjects and in patients with COPD [3] . This hypoventila tion is most severe during R E M sleep. The cause of this phenomenon is not fully understood but may be related to a decrease in brainstem respi ratory activity, diminished respiratory responses to hypoxia and hypercapnia during R EM sleep, and a loss of inspiratory activity of intercostal muscles and accessory respiratory muscles. The latter is due to the REM -sleep-related supraspinal inhibition of the gamma motor neuron drive.
«
Since the gamma m otoneuron innervation of the diaphragm is sparse, this muscle is relatively spared. These changes occur in patients with COPD as well as in healthy subjects, but the consequences are worse in the first group. Firstly, patients with COPD often have somewhat low ered arterial oxygen tensions awake. The starting position on the oxygen saturation curve is closer to the steep part, so a small drop in P a 0 2 during the night causes a large fall in S a 0 2. Secondly, the flattened diaphragm cannot compensate for the decreased activity of intercostal and accessory muscles during R EM sleep. Thirdly, desaturating patients have a larger decrease in functional residual capacity during hypopnoea [2] . Finally, the ventilatory responses in some patients with COPD during wakefulness are already lowered, thus further contributing to the degree of noctur nal desaturations [4] .
Ventilation / perfusion inequality: Previously, this was considered as the major cause of REMsleep-related hypoxaemia in patients with COPD 298 YF . Heijdra et a l / Netherlands Journal o f Medicine 47 (1995) 296-301 [3] . However, these studies were based on the assumption that there is a steady state of gas transfer, which does not exist during REM sleep [10] . It is inevitable, though, that hypoventiiation during R E M sleep is accompanied by some alter ation in ventilation/perfusion matching.
Abnormal hypercapnic and hypoxic responses: Ventilatory responses during wakefulness to hypercapnia and hypoxia seem to be lower in hy poxic patients [3] ,
Obstructive sleep apnoea / hypopnoea syndrome (OSAHS): OSAHS, defined as a sleeping disor der in which obstructive apnoea/hypopnoea events occur more than 10 times per sleeping hour, may affect 1-4% of the general population [3] . Thus, a similar percentage of patients with COPD may also suffer from OSAHS, but the prevalence is most probably not higher than in the general population.
Consequences o f nocturnal hypoxaemia
W hen desaturations are severe and result in nocturnal hypoxaemia, side-effects may occur. Nocturnal hypoxaemia is associated with pul monary hypertension [11] [12] [13] [14] , which causes cor pulmonale [15, 16] , Furthermore, polycythaemia may exist [17] . Cardiac arrhythmia is an uncom mon complication, but premature ventricular complexes, bradycardia and tachycardia have been described [18] . In the study of Levi-Valensi and colleagues [11] a correlation (r = 0.33) was found betw een the total duration of saturation dips and pulmonary hypertension in 40 patients with COPD and a daytime P a 0 2 between 8.0-9.3 kPa (60-70 mmHg). Pulmonary hypertension was only present in 6 out of 18 patients who desatu rated. These findings are in line with the data published by Fletcher and co-workers [12] . These authors found that the systolic pulmonary arterial pressure was significantly higher in desaturating (n = 36) than in non-desaturating (n = 13) pa tients with COPD and with a daytime P a 0 2 > 8 kPa (60 mmHg) (33 versus 26 mmHg, p < 0.01).
In the study of Boysen and colleaques [13] the effects of hypoxaemic episodes on the pulmonary artery pressure (Pap) during the night were stud ied in 4 patients with COPD. All nocturnal episodes of desaturations were accompanied by elevations in the Pap. Low flow oxygen abolished the drops in arterial oxygen saturation and no elevations in the Pap were observed. Weitzenblum and co-workers [14] investigated prospectively the changes in P a 0 2 and Pap in 93 hypox aemic patients with severe COPD for at least 5 years. In 27 patients an increase > 5 mmHg in the Pap was observed. Only in this patient group was a marked worsening of the P a 0 2 seen, which was not observed in the remaining 66 patients. There was a significant correlation between the change in Pap and P a 0 2 ( r = -0.50, p <0.001). All these studies suggest that nocturnal hypox aemia is associated with the development and progression of pulmonary hypertension.
The relationship between daytime or nocturnal hypoxaemia and cor pulmonale was studied by Midgren and colleagues [16] . Seven of the 21 included patients with COPD had suffered from right ventricular failure at least once. They had lower P a 0 2 and higher P a C 0 2 levels than the patients without a history of right heart failure. They were more hypoxaemic during the night. In the group as a whole no correlations were found between daytime oxygenation and right ventricu lar hypertrophy. However, oxygen saturation dur ing the night and right ventricular hypertrophy were inversely related (r = -0.56, p < 0.01). Therefore, in normoxic patients during the day but with signs of right heart failure a polysomnog raphy is advised.
The effects of nocturnal hypoxaemia on sur vival are not clear yet. One study is available in which survival in desaturating and non-desaturating patients is compared [1] . One hundred and sixty-nine patients with COPD and a FEV t of 35% predicted, who were all normoxaemic (daytime PaO 2 > 8.0 kPa [60 mmHg]), were inves tigated. Desaturating patients had a worse sur vival than non-desaturating patients (mean sur vival 2.9 [1.7] and 3.7 [1.7]) years, respectively). Also, 5-year survival was significantly better in the non-desaturating group (after stratification for oxygen suppletion). However, this was a retro spective multicentre study in which patients were included who were already being treated with oxygen.
Treatment of nocturnal hypoxaemia
5.1, Supplemental oxygen
Studies on the effects of oxygen have only been performed in patients who were also hypoxaemic during the day. In these studies an im provement of the quality of life [19] , some rever sal of ECG changes (less right axis deviation or the loss of the finding of " p-pulmonale" [19] ) and a decrease in the pulmonary artery pressure com bined with an increase in cardiac output [20] were observed. Supplemental oxygen during the night can be given safely because it improves nocturnal oxygenation with only a small rise in P a C 0 2 [21] . Nocturnal oxygen supply should be titrated indi vidually during a full night and should be con trolled by oximetry. The mean nocturnal arterial oxygen saturation should be more than 90% [22] .
Ventilatory stimulants
Stimulating agents may be considered if any reserve-capacity of the ventilatory pump is pre sent. The progestogens medroxyprogesterone ac etate and chlormadione acetate increased day time P a 0 2 and decreased PaC0 2, but the effects on nocturnal saturation were marginal or absent in the whole group of patients. Nevertheless, for the individual patient, chlormadione acetate may have a substantially positive effect on day-and nighttime blood gas values [23, 24] . Acetazolamide, a carbonic anhydrase inhibitor, stimulates ventilation presumably by inducing metabolic aci dosis. In a 1-week double-blind, placebo-con trolled study it caused an improvement in the mean daytime P a 0 2 of 1.9 kPa (14 mmHg) and in the mean nocturnal saturation of 4% [24] . How ever, acetazolamide may be ineffective in some patients. Daytime parameters, however, failed to select the non-responders. Recently, Mulloy et al. [25] showed in a 3-week double-blind, placebocontrolled study that theophylline improved gas exchange during sleep in 10 patients with severe COPD. The mean S a 0 2 asleep improved by 2% while the mean transcutaneously measured P C 0 2 asleep decreased by 0.5 kPa (4 mmHg). Loop diuretics have an adverse effect on nocturnal saturation since they can result in a metabolic alkalosis and blunt the respiratory drive [15] .
Assisted ventilation
Continuous positive pressure ventilation dur ing the night, administered through a nasal mask, can effectively reduce inspiratory muscle effort during sleep, but S a 0 2 and transcutaneously measured P C 0 2 were unaffected [26] . The effects of nasal intermittent positive pressure ventilation were described in an uncontrolled study by Car roll and co-workers [27] . They showed in 4 hypoxaemic patients with COPD and with a mean FEVj of 19% of the predicted value that daytime P a 0 2 did not change significantly while daytime P a C 0 2 decreased by 1.1 kPa (14.3 mmHg). Oxy genation during the night improved. This was shown by a decrease in the time spent below 90% S a 0 2 from 100 to 40% of the total monitoring time. However, the patients slept less well, as shown by a decrease in R EM sleep from 12 to 5% of the monitoring time.
Training o f the respiratory muscles
Target-flow inspiratory muscle training (TF-IMT) is the most recently described form of ther apy [28] . During 10 weeks, 10 patients with COPD underwent TF-IM T at 60% of their maximal in spiratory mouth pressure (P Imax) and 10 control patients with COPD received sham TF-IM T at 10% of PI m iU i • Two times a day patients trained on an incentive flow m eter with an added resis tance for 15 min. P I max, maximal inspiratory transdiaphragmatic pressure (Pdi), and respira tory muscle endurance improved significantly in the 60% training group. No changes were found in the sham training group. The improved respi ratory muscle function resulted in a mean in crease in mean nocturnal saturation by 2 % (p = 0.01); the most pronounced improvements (up to 7%) were found in patients with the lowest noc turnal saturations.
Clinical consequences and recom m endations
Although positive effects of the different forms of therapy on nocturnal saturation have been described, no placebo-controlled studies have been published on the effects on pulmonary artery pressure, cor pulmonale and survival. So far it has not been recommended, therefore, to pre scribe oxygen to patients with mild nocturnal hypoxaemia only, since it is an expensive form of therapy. An exception is made for patients with severe hypoxaemia (S a 0 2 < 85%) for more than 2 hours while sleeping, because it is unlikely that such episodes are harmless [22] . Acetazolamide, progestogens, theophyllines and inspiratory mus cle training are modalities that can be used to treat nocturnal hypoxaemia, but their effects on the occurrence of complications in the long term are not known. Based upon the above-mentioned considera tions, nocturnal hypoxaemia (S a 0 2 < 90%) in patients with COPD should be treated in the following way (Table 1 ). Supplemental oxygen for as close to 24 h /d a y as is possible [29] should be administered if nocturnal hypoxaemia is present in combination with a daytime P a 0 2 between 7.4-8.0 kPa (55-60 mmHg) with evidence of polycythaemia (Ht > 55%) or pulmonary hyperten sion (mean pulmonary artery pressure > 3 kPa [20 mmHg]) or clinical signs of cor pulmonale [22, 30] . Nocturnal oxygen therapy may be consid ered in patients with severe episodes of hypox aemia (S a 0 2 < 85%) for more than 2 hours dur ing the night [22] . The oxygen dose should be sufficient to raise the saturation above 90% [22] . Acetazolamide, progestogens, theophylline and respiratory muscle training may be considered to treat patients with mild hypoxaemia only during the night. Polysomnography should be used for diagnosing nocturnal hypoxaemia, its underlying mechanisms, and for establishing the presence of REM sleep in the diagnostic night. Oximetry can be used for screening purposes, and for titrating the required amount of supplemental nocturnal oxygen.
